Leiden, The Netherlands – 27 February 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, received the ‘Company Award’ at the EURORDIS Black Pearl Gala Dinner in Brussels last night.
Author: Willem van Lawick
Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™
Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Health Canada for its new clinical study with ATIR™. This study will be a Phase II international multi-center study with clinical sites in Canada and… Continue reading Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™
Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs
Leiden, The Netherlands – 7 February 2013 – Prosensa Therapeutics, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced the appointment of Larry Bell, M.D. as its Vice President of Regulatory Affairs. Dr. Bell will be based in the USA.
Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio
Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designation in the EU and the US for all of its compounds for the treatment of Duchenne muscular dystrophy (DMD).
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regarding the Company’s lead product ATIR™. ATIR™ is a cell-based product that enables stem cell transplantations from mismatched… Continue reading Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
